Some Joints May Be Pre‑Programmed for Rheumatoid Arthritis, Oxford Researchers Reveal

For years doctors have puzzled over why rheumatoid arthritis (RA) repeatedly attacks the same handful of joints while sparing others. A team from the University of Oxford’s Kennedy Institute thinks the answer might be hiding in the womb.

Using a blend of single‑cell sequencing, 3D X‑ray imaging and clever image‑analysis tools, the researchers mapped developing human finger joints in unprecedented detail. What they found was striking: the proximal interphalangeal (PIP) joints—those most often inflamed in RA—already contain more synovial tissue and a larger pool of PI16‑positive fibroblasts than the distal interphalangeal (DIP) joints that are usually left untouched.

These PI16⁺ fibroblasts hang out around blood vessels and where tendons meet bone, and they react to inflammatory cues in a way that differs from their PI16‑negative cousins. In short, they seem wired to amplify immune signals, potentially giving inflammation a foothold that other joints simply lack.

'We’ve known that RA targets specific joints, but we never imagined the groundwork could be laid before birth,' says Christopher Buckley, Kennedy Professor of Translational Rheumatology. 'It’s not just the immune system; the tissue itself may be primed for disease.'

The study also showed that developing joints are dominated by structural cells—fibroblasts and cartilage‑forming cells—rather than immune cells. Local factors such as low‑oxygen pockets appear to steer fibroblasts toward a synovial‑lining fate, hinting that tiny variations in the embryonic environment could echo decades later.

High‑resolution scans at the Diamond Light Source confirmed that the architecture of PIP joints is genuinely different, with more abundant and oddly organized synovium. Together, the cellular and structural disparities offer a plausible why‑this‑joint‑gets‑hit scenario.

Sarah Davidson, the study’s post‑doctoral lead, adds, 'Finding these distinct cell populations before birth was a surprise. It suggests we might one day intervene very early—perhaps even before symptoms appear—to steer joint development toward a more resistant profile.'

If these embryonic clues hold up, they could reshape how we think about preventing or treating RA, shifting some focus from solely modulating the immune system to also considering how joint tissue is built in the first place.